难治性高血压治疗新药——Aprocitentan  

Aprocitentan—A New Drug for Treatment of Refractory Hypertension

作　　者：王钰然 孙雪林[2] 郑丽[3] WANG Yu-ran;SUN Xue-lin;ZHENG LI(Department of Obstetrics and Gynecology,731 Hospital,China Aerospace Science and Technology Group,Beijing 100074,China;Department of Pharmacy,Beijing Hospital,National Geriatrics Center,Institute of Geriatrics,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Pharmacy,731 Hospital,China Aerospace Science and Technology Group,Beijing 100074,China)

机构地区：[1]中国航天科工集团七三一医院妇产科,北京100074 [2]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京100730 [3]中国航天科工集团七三一医院药剂科,北京100074

出　　处：《中国合理用药探索》2024年第11期27-30,共4页Chinese Journal of Rational Drug Use

基　　金：中央高水平医院临床科研业务费资助项目(BJ-2023-200);国家重点研发计划资助项目(2020YFC2009001)。

摘　　要：难治性高血压(RH)是一种严重影响人类健康的特殊高血压类型,尽管有详细管理办法和较多药物,但仍有部分患者会出现血压难以控制的情况。2024年3月19日FDA批准aprocitentan用于RH治疗,为该类疾病提供了新的治疗方案。Aprocitentan是一种口服活性的双重内皮素-1(ET-1)受体拮抗剂,通过阻止ET-1与ETA/ETB受体的结合发挥治疗高血压的作用,且其可增强其他抗高血压药物的降压作用,为RH患者提供更多的心脑血管保护,最常见的不良反应是轻度至中度水肿或液体潴留。本文就其作用机制、药动学、临床试验研究及安全性进行综述。Refractory hypertension(RH)is a special type of hypertension that seriously affects human health.Although there are detailed management approaches and many drugs available,some patients still have uncontrollable BP.On March 19,2024,the U.S.Food and Drug Administration(FDA)approved aprocitentan,a new drug for treating patients with RH.Aprocitentan is an orally active dual endothelin-1(ET-1)receptor antagonist that treats hypertension by preventing the binding of ET-1 to ETA/ETB receptors.It can enhance the antihypertensive effect with other antihypertensive drugs and provide more profound cardiovascular protection for RH patients.The most common adverse reaction is mild to moderate edema or fluid retention.The mechanism of action,pharmacokinetics,clinical trials and safety of Aprocitentan were reviewed in this article.

关 键 词：aprocitentan 难治性高血压 双重内皮素-1 临床试验研究 安全性 

分 类 号：R972.4[医药卫生—药品]